Assessment of Safety and Efficacy of Tofacitinib, Stratified by Age, in Patients from the Ulcerative Colitis Clinical Program
Gary R. Lichtenstein(University of Pennsylvania), Edward V. Loftus(Mayo Clinic), Chinyu Su(Pfizer (United States)), Nervin Lawendy(Pfizer (United States)), Donna T. Judd(Pfizer (United States)), Hongjiong Shi(Pfizer (United States)), Leonardo Salese(Johnson & Johnson (United States)), Brian Bressler(University of British Columbia), Carlos Fernando de Magalhães Francisconi(Universidade Federal do Rio Grande do Sul), Thomas V. Jones(Pfizer (United States)), Gosford Sawyerr(Pfizer (United States)), Séverine Vermeire(KU Leuven)
Cited by 39
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k